AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
June 18 (Reuters) - British drugmaker AstraZeneca Plc AZN.L on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.
Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co MRK.N, can now be used in patients who are in response following chemotherapy for BRCA-mutated ovarian cancer in Europe, AstraZeneca said.
BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Wall St Week Ahead-Buoyant U.S. stocks at odds with downbeat market signals
- Fed faces tougher task in deciding whether to cut U.S. rates
- Colombia's central bank holds key lending rate at 4.25%, as expected
- Amazon, Walmart's Flipkart unlikely to respond to key queries in India antitrust study -sources